AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform

AbbVie Inc. (NYSE:ABBV) is included among the 15 Dividend Stocks to Buy for Steady Income. AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform On March 17, Alloy Therapeutics announced an agreement with AbbVie Inc. (NYSE:ABBV) to develop a new antibody platform. The goal is to discover potent and specific antibodies for targets that current technologies struggle to address. Under the multi-year deal, Alloy will receive an upfront payment, along with an additional payment tied to del ...